Highest-materiality recent filing
Clarivate closes $600M sale of Life Sciences & Healthcare to Altaris; segment head Levy departs
Deal consideration: $500M cash at closing plus a $75M unsecured senior note from an Altaris affiliate and $25M deferred cash payable by January 31, 2028.
Clarivate appoints Michael Easton as CFO effective Aug 8, 2026; Jonathan Collins resigns
Jonathan Collins resigns as EVP & CFO effective Aug 7, 2026; departure not due to any disagreement.
Clarivate Q2 revenue down 5.5% to $587M; net loss $269M on goodwill impairment; reaffirms FY outlook
Q2 total revenues $587.3M, down 5.5% YoY; organic revenue -1.5% as subscription +0.7% offset by transactional -15.7%.
Clarivate sells Life Sciences & Healthcare business to Altaris for $600M
Purchase price $600M: $500M cash at close, $25M deferred, $75M senior note.
Clarivate sells Life Sciences & Healthcare segment to Altaris for $600M
Deal value $600M: $500M cash at close, $25M deferred cash, $75M seller note.
Clarivate appoints Simon Webster as President of IP segment; Maroun Mourad departs
Maroun Mourad, President IP, will depart June 9, 2026, and remain in advisory role through Sept 30, 2026.
Clarivate reports Q1 2026 earnings: organic revenue up 0.6%, reaffirms full-year outlook
Total revenues $585.5M, down 1.4% from prior year; organic revenue up 0.6%.
Clarivate Q4 revenue $617M, down 7%; pursues LS&H sale; FY26 FCF ~$400M
Q4 net income $3.1M vs loss $191.8M; adjusted EPS $0.20 vs $0.21. Full-year adjusted EBITDA $1,001.8M.
Clarivate redeems remaining $100M 2026 notes; buys back $225M shares in FY2025
Redeemed remaining $100M principal of 4.50% senior secured notes due 2026 on Jan 30, 2026, using cash on hand.
Clarivate Q3 revenue flat at $623.1M, net loss narrows; raises 2025 revenue outlook
Organic ACV grew 1.6% YoY; recurring revenue mix improved to 88% of total revenue (up 800 bps).
Clarivate appoints Maroun S. Mourad as President, IP; Gordon Samson to retire by year-end
Gordon Samson to depart President, IP role on Sept 7, 2025; will remain non-executive until Dec 31, 2025.
Clarivate Q2 revenue $621.4M (-4.4% YoY); organic growth 0.5%; reaffirms 2025 outlook
Total revenue $621.4M, down 4.4% YoY due to divestitures; organic revenue +0.5%.
Clarivate closes $500M incremental term loan, redeems $500M of 2026 notes
New $500M incremental term B loans added under credit agreement, maturing 2031, interest rate of Term SOFR + 3.25%.
Clarivate Q1 rev $593.7M (-4.4% YoY); organic +0.3%; net loss widens; outlook reaffirmed
Total revenue $593.7M (-4.4% YoY); organic revenue up 0.3%, recurring organic +0.6%.
Clarivate Q4 revenue $663M (-3% YoY), adj. EPS $0.21; initiates strategic alternatives review
Full year 2024 revenue $2.56B (-2.7% YoY); net loss -$636.7M improved from -$911.2M.
Clarivate authorizes $500M share repurchase program for 2025-2026
Board authorized $500M share repurchase via open-market buys from Jan 1, 2025 to Dec 31, 2026.
Clarivate Q3 revenue down 3.9%, posts net loss; withdraws 2024 outlook
Revenue $622.2M (-3.9% YoY); organic revenue -2.6% with transactional sales down 13.6%.
Clarivate appoints Matti Shem Tov as CEO effective Aug 9; Jonathan Gear steps down
Gear receives $4.375M lump sum, pro-rated bonus, accelerated RSUs, and 18 months COBRA reimbursement.
Clarivate Q2 2024 revenue down 2.8%, adjusted EPS $0.20, reaffirms FY outlook
Revenues $650.3M, down 2.8% YoY; organic revenue declined 0.6% with subscription growth offset by transactional/other.
Clarivate Q1 net loss $93.8M; revenue down 1.3%; adjusted EPS -22%
Net loss per diluted share $0.14 vs income $0.04 YoY; adjusted diluted EPS $0.14, down 22.2%.
Clarivate enters investment pact with Exor; Exor to nominate director, subject to standstill
Exor, holding 10.1% of Clarivate shares, will nominate its COO Suzanne Heywood for board election at 2024 annual meeting.
Clarivate Q4 net loss $863M on $845M impairment; adj EPS $0.23 +4.5%
Q4 revenues $683.7M +1.2% YoY; organic revenue growth 0.1%.
Clarivate refinances $2.15B term loan, lowers margin and extends revolver to 2029
New $2.150 billion term loan tranche matures in 2031 at SOFR + 275 bps, down from prior margin.
Clarivate launches $2.2B term loan refinancing; expects $800M-$900M goodwill impairment in Q4 2023
Refinancing of 2026 Term Loan B with new $2.2B, 7-year facility maturing in 2031, subject to market conditions.
Clarivate Q3 revenues $647M, up 1.8%; adj. EPS $0.21, up 5%; reaffirms FY23 outlook
Revenue $647.2M, up 1.8% vs Q3 2022; organic revenue growth 1.7%.
Clarivate Q2 net loss $141.7M; revenue down 2.6%; lowers 2023 outlook
Revenue $668.8M (-2.6% YoY); organic revenue -0.4%. Net loss $141.7M vs. income $43.7M prior year.
Clarivate Q1 revenue $629M (-5% YoY); adj. EPS $0.18; CRO departs; reaffirms FY outlook
Revenue $629.1M (-5% YoY; -3.1% constant currency); organic revenue -0.2% due to MarkMonitor divestiture and FX.
Q4 revenue $675.3M (+20.4% YoY); organic revenue +0.5%; subscription +2.5% organic.
Upon the Closing and in connection with the Transaction, Henry Levy, Clarivate’s President, Life Sciences & Healthcare, terminated employment with a subsidiary of Clarivate.
Maroun S. Mourad, President, Intellectual Property of Clarivate Plc (the “Company”) will depart from his position, effective June 9, 2026.
On February 25, 2025, Michael J. Angelakis notified Clarivate Plc (the “Company”) of his decision to retire from the Board of Directors of the Company (the “Board”), effective upon the re-election of members of the Board at the Company’s 2025 Annual General Meeting of Shareholders to be held on May 7, 2025, and withdrew from consideration for re-election as a member of the Board.
Jonathan Gear, Chief Executive Officer of Clarivate Plc (the “Company”) will depart from his position and step down as a member of the board of directors (the “Board”), effective August 9, 2024.
On August 6, 2024, the Company announced that Matitiahu (Matti) Shem Tov, age 63, will assume the role of Chief Executive Officer and will join the Board, effective as of August 9, 2024.
On July 23, 2024, Richard Roedel notified Clarivate Plc (the “Company”) of his retirement from the Board of Directors of the Company, effective as of December 31, 2024.
Steen Lomholt-Thomsen, Chief Revenue Officer of Clarivate Plc (the “Company”) will depart from his position, effective July 1, 2023.
Balakrishnan Iyer, Konstantin Gilis and Roxane White, members of the board of directors, were stepping down from the board, effective on December 19, 2022.
Balakrishnan Iyer, Konstantin Gilis and Roxane White, members of the board of directors, were stepping down from the board, effective on December 19, 2022.
Balakrishnan Iyer, Konstantin Gilis and Roxane White, members of the board of directors, were stepping down from the board, effective on December 19, 2022.
Mr. Stead has informed Clarivate that following the Board meeting scheduled for October 20, 2022, he will retire from the Board of Directors.
the retirement of Jerre Stead from that role.
Max materiality 0.85 · Median 0.60 · Most common event earnings